Skip to main content
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.

Methallylescaline

Methallylescaline molecule structureMethallylescaline molecule structure
Psychoactive Class
HallucinogenPsychedelic
Chemical Class
Scaline

Methallylescaline (MAL) is a synthetic1 psychedelic1 of the substituted phenethylamine class and a structural analog of mescaline.2 Its effects were first described by Alexander Shulgin in PiHKAL, with anecdotal reports suggesting it most closely resembles mescaline among the various mescaline analogs, producing both hallucinogenic and stimulantcitation needed properties. Very little data exists regarding its pharmacology, metabolism, or toxicity,3 and it has minimal history of human use.

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~5 mg
Light5-25 mg
Moderate25-40 mg
Strong40-60 mg
Heavy60+ mg

Methallylescaline has a steep dose-response relationship, meaning relatively small increases in the amount taken may result in disproportionately stronger effects. Careful attention to precise dosing is advisable.

Duration

Onset20-60 minutes
Come Up30-90 minutes
Peak3-5 hours
Offset2-4 hours
After Effects3-5 hours
Total6-12 hours

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

Effects vary widely by individual, dose, and context.

Physical

Spontaneous tactile sensationsStimulationNauseaTactile enhancementBodily control enhancementPupil dilationWakefulness

Cognitive

Emotion enhancementThought accelerationNovelty enhancementTime distortionAnalysis enhancementPersonal bias suppressionConceptual thinkingImmersion enhancementMemory suppressionEgo deathThought loopsDelusionsThought disorganization

Visual

Distortions

Enhancements

Hallucinatory States

Transformations

Auditory

EnhancementsDistortionsHallucinations
Forked from Subjective Effect Documentation work byJosie Kins August 2016.

See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)

Pharmacology

Pharmacodynamics

Methallylescaline acts as an agonist at serotonin 5-HT2 receptors,citation needed with primary activity at the 5-HT2A receptor. It has been described both as a potent 5-HT2A agonist4 and as a likely 5-HT2A partial agonist. It also interacts with the 5-HT2C receptor.4

Pharmacokinetics

The metabolism of Methallylescaline has been studied. Methallylescaline is proposed to undergo hydroxylation, O-dealkylation, carboxylation, deamination and dihydroxylation of the allyl group.citation needed

Metabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance
Tolerance to the effects of methallylescaline develops almost immediately following ingestion.
Baseline Reset
Approximately 7 days without further consumption
Half Tolerance
Approximately 3 days
Cross Tolerance

Psychedelics

Harm Potential

Addiction & Dependence

Psychological

Extremely Low

Methallylescaline is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.

Psychosis Risk

Delusion is listed among possible cognitive effects. Some reports mention experiences described as 'shades of what might become amnesia' and 'losing immediate contact,' though formal psychosis risk has not been evaluated due to the substance's limited research history.citation needed

History & Culture

Methallylescaline was first synthesized and explored by American chemist Alexander Shulgin, who initially experimented with the compound in 1981. The following year, in 1982, Shulgin discovered its hallucinogenic properties. He subsequently documented his findings in his 1991 book PiHKAL: A…

Trip Reports

Loading related reports

Preparing section content

Still loading. Refresh if this section does not appear.

Legality

By Country

Illegal2
Germany flagGermanyIllegal
United Kingdom flagUnited KingdomIllegal
Controlled / restricted2
United States flagUnited StatesRestricted
Switzerland flagSwitzerlandRestricted
Not scheduled1
Canada flagCanadaNot scheduled

References

Citations

  1. Alexander Shulgin, & Ann Shulgin. (1991). PiHKAL #99: MAL. https://www.erowid.org/library/books_online/pihkal/pihkal099.shtml123
  2. Tang Y, Xu L, Guo Z, Zhao J, Xiao Y, Xiang P, & Yan H. (2025). Metabolism study of two phenethylamine-derived new psychoactive substances using in silico, in vivo, and in vitro approaches. 99(6), 2367-2378. https://doi.org/10.1007/s00204-025-04010-61
  3. Sunjoo Kim, Ju Hyun Kim, Dong Kyun Kim, Jaesin Lee, Sangwhan In, & Hye Suklee. (2018). In vitro metabolism of methallylescaline in human hepatocytes using liquid chromatography-high resolution mass spectrometry. 9(3), 86-90. https://doi.org/10.5478/msl.2018.9.3.861
  4. Karolina E. Kolaczynska, Dino Luethi, Daniel Trachsel, Marius C. Hoener, & Matthias E. Liechti. (2022). Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines. 12, Article 794254. https://doi.org/10.3389/fphar.2021.7942541234
  5. Controlled Drugs and Substances Act (current consolidated full text). laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/c-38.8/FullText.html1
  6. Controlled Drugs and Substances Act, Schedule III. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/C-38.8/section-sched95602.html1
  7. Controlled Drugs and Substances Act, Schedule I. laws-lois.justice.gc.ca (n.d.). https://www.laws-lois.justice.gc.ca/eng/acts/C-38.8/section-sched95314.html1
  8. PubChem PUG REST: Methallylescaline CID 44350127 structure properties. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/44350127/property/IUPACName,CanonicalSMILES,IsomericSMILES,MolecularFormula/JSON1
  9. NIH PubChem CID 44350127 synonyms. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/44350127/synonyms/JSON12345
  10. Health Canada's controlled substances status determination process. canada.ca (n.d.). https://www.canada.ca/en/health-canada/corporate/mandate/regulatory-role/what-health-canada-regulates-1/controlled-substances-precursors/overview-substance-control-status-determination-process.html1

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Lyrea avatar
    Step 2 · First-pass review

    A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes8 human edits · latest

Times are UTCNewest first

30 August 2026

  1. Lyrea · Edited in History & Culture › Content

  2. Lyrea · Added a source: Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story

  3. Lyrea · Edited in History & Culture › Content

  4. Lyrea · Added a citation in History & Culture › Content

  5. Lyrea · Added a citation and reworded 6 words in Pharmacology › Pharmacokinetics

  6. Lyrea · Changed a word in Pharmacology › Pharmacokinetics

  7. Lyrea · Reworded 3 words in Pharmacology › Pharmacokinetics

  8. Lyrea · Reworded 8 words in Pharmacology › Pharmacokinetics

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Methallylescaline article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.